

Discover & Deliver: Biden Administration Urged to Release Vaccines to Hard Hit Nations while New ‘Dark-Horse’ Vaccine Nears FDA Authorization

With more than [1.04 billion COVID-19 vaccine doses](#) administered around the world, it is easy to forget that people are still contracting COVID-19 at staggering rates. The [crisis in India](#) is an acute reminder of the ways coronavirus continues to devastate communities over the 14 months since the onset of the global pandemic.

What’s new: Yesterday, the [administration announced](#) the U.S. will share as many as 60 million doses of the AstraZeneca vaccine, as soon as the vaccines are cleared by the Food and Drug Administration’s safety and quality review.

More help on the way: The Novavax, “dark-horse” [coronavirus vaccine](#), may also be able to help bolster the global vaccine supply. The vaccine is 89.3% effective at preventing coronavirus infection, based on a [large Phase 3 clinical trial](#) in the UK.

Novavax plans to provide COVAX with 1.1 billion doses of the Novavax vaccine, many of which will be produced by India’s Serum Institute.

Why it matters: Critics have been quick to suggest that intellectual property (IP) has been a barrier to the distribution of global vaccines.

On the contrary, IP provides the legal and economic basis that allows companies like Novavax – which currently has no FDA-approved medicines – to collaborate with global partners to supercharge the production and distribution of the vaccine.

As [pressure mounts](#) to waive IP during the global pandemic, the U.S. Chamber stands strong behind the innovators responsible for the discovery and delivery of multiple effective vaccines in record time.

—**Kelly Anderson, Senior Director, Health and Drug Policy, Global Innovation Policy Center**